Abciximab (C7E3) 是一种小鼠/人嵌合单克隆抗体，是一种糖蛋白 IIb/IIIa（glycoprotein IIb/IIIa）抑制剂。 Abciximab 通过与糖蛋白 IIb/IIIa、vitronectin 和 Mac-1 受体结合抑制血小板聚集和白细胞粘附。
货号:ajcx39890
CAS:143653-53-6
分子式:N/A
分子量：N/A
溶解度:N/A
纯度：98%
存储：Store at -20°C
库存：现货

Background:

Abciximab (C7E3), a chimeric mouse/human monoclonal antibody, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors[1].

Abciximab (C7E3) inhibits platelet aggregation induced by physiologic and pathologic agonists by binding to the platelet αIIbβ3 integrin[2].Abciximab appears to have similar affinity for the αIIbβ3 and αvβ3 integrins and redistributes between them[2].

Abciximab (C7E3) (0.25 mg/kg/day; i.v.; 28 days) effectively prevents neointimal hyperplasia[2].

[1]. Ibbotson T, et al. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. Drugs. 2003;63(11):1121-63.
[2]. Wu CH, et al. Mechanisms involved in the inhibition of neointimal hyperplasia by abciximab in a rat model of balloon angioplasty. Thromb Res. 2001 Feb 1;101(3):127-38.